Alternative Pathway Complement Activation with Possible Complement-Mediated Disease
This complement profile strongly suggests ongoing alternative pathway (AP) activation with consumption of complement components, most consistent with a complement-mediated thrombotic microangiopathy (TMA) such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, or another complement-driven inflammatory condition.
Interpretation of the Complement Panel
Your pattern shows:
- Decreased C3, Factor B, Factor I, and Factor D = consumption from AP activation
- Normal C4 and Bb fragments = classical pathway intact, but see caveat below
- Elevated sC5b-9 = terminal pathway activation with membrane attack complex formation
- Low Factor D (20% below normal) = particularly concerning since Factor D is not consumed during complement activation
Why This Pattern Matters
The combination of low C3 with normal C4 indicates selective alternative pathway dysregulation rather than classical pathway activation 1. In C3 glomerulopathy, patients demonstrate significantly lower C3 (P<0.001) and Factor B (P<0.001) compared to controls, with elevated breakdown products including Bb (P<0.001) 1. However, your normal Bb fragments are unusual and may indicate either:
- Timing of sample collection (Bb is rapidly cleared)
- Laboratory assay limitations
- Consumption has already occurred
The elevated sC5b-9 is critical - it confirms that complement activation is proceeding to terminal pathway completion and forming membrane attack complexes 2, 3. This marker correlates with end-organ injury and increased morbidity 4. In complement-mediated diseases, sC5b-9 elevation indicates active disease requiring urgent evaluation 2.
The Factor D Anomaly
Factor D deficiency at 20% below normal range is highly unusual and clinically significant. You're correct that Factor D doesn't get consumed during complement activation - it's a serine protease that cleaves Factor B but remains intact 5. Low Factor D suggests either:
- Genetic Factor D deficiency (rare but described)
- Urinary loss (in nephrotic-range proteinuria)
- Consumption in overwhelming complement activation (extremely rare)
- Laboratory artifact (least likely if repeated)
This finding, combined with low Factor I, raises concern for genetic complement regulatory protein deficiencies predisposing to uncontrolled AP activation 6.
Most Likely Diagnoses to Evaluate
1. Atypical Hemolytic Uremic Syndrome (aHUS)
- Look for: hemolytic anemia, thrombocytopenia, acute kidney injury, elevated LDH, schistocytes on blood smear
- Critical caveat: Not all three features (anemia, thrombocytopenia, renal involvement) need to be present at onset 6
- Check: CBC, peripheral smear, LDH, haptoglobin, creatinine, urinalysis
- Genetic testing should include: CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, CFB 6
2. C3 Glomerulopathy
- Look for: hematuria, proteinuria, declining renal function
- This pattern matches published C3G profiles with low C3, low Factor B, elevated sC5b-9 1
- Definitive diagnosis requires kidney biopsy showing dominant C3 deposition on immunofluorescence 1
- Check for C3 nephritic factor and anti-Factor H antibodies 7
3. Systemic Complement Activation
- Consider: sepsis, autoimmune disease (especially with IBD), systemic inflammatory conditions
- The pattern can occur in septic shock with AP activation 8
- Look for underlying triggers: infection, autoimmune disease, malignancy
Immediate Next Steps
Clinical assessment for TMA features:
- Complete blood count with peripheral smear
- LDH, haptoglobin, indirect bilirubin
- Creatinine, urinalysis (proteinuria, hematuria)
- Blood pressure
Additional complement testing:
- C3 nephritic factor
- Anti-Factor H antibodies 7
- Repeat Factor D level to confirm
- Consider Factor H protein level
Genetic testing if clinical suspicion for aHUS or C3G:
Kidney biopsy if renal involvement present:
- Essential for C3G diagnosis
- Will show terminal complement complex (TCC) deposition pattern 3
Critical Pitfalls to Avoid
- Don't wait for "classic" TMA triad - absence of marked thrombocytopenia or anemia doesn't exclude diagnosis 6
- Don't assume normal Bb excludes AP activation - timing and assay limitations matter
- Don't ignore the low Factor D - this is not explained by consumption and warrants investigation
- Don't delay genetic testing - results take weeks and shouldn't delay treatment decisions in acute TMA 6
Treatment Considerations
If aHUS is confirmed or highly suspected clinically, complement inhibition with eculizumab or ravulizumab should be initiated urgently before genetic results return, as mortality is high in untreated disease 6. The elevated sC5b-9 provides evidence of terminal pathway activation that these agents would block 2.
Refer urgently to nephrology for definitive diagnosis and management, as this pattern indicates active complement-mediated disease requiring specialized evaluation and potential complement-directed therapy.